How an untested drugs scandal could lead to better clinical practice

Cancer researchers and patients from all over the world can learn valuable lessons from a recent Brazilian scientific scandal, according to a new policy paper. In Brazil, the distribution by „researchers“ to patients of an untested compound called phosphoethanolamine (PHOS) led to a widely publicized scientific debacle. (Mehr in: Cancer News — ScienceDaily)